|drug1532||Hydroxychloroquine Sulfate 200 MG [Plaquenil] Wiki||0.71|
|drug2555||Placebo oral capsule Wiki||0.58|
|drug2557||Placebo oral tablet Wiki||0.17|
|D019337||Hematologic Neoplasms NIH||0.38|
There is one clinical trial.
The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among patients with COVID-19 and hematological malignancies.
Description: Locally evaluated rate of viral response. Favorable response is defined as (1) complete response : negative PCR (absence of detectable signal with a minimum of 40 cycles) or (2) major response : detectable signal but with an increased number of cycles > or egal to 10 compared to initial PCR. Response failure is defined as (1) minor response : detectable signal but with an increased number of cycles < 10 compared to initial PCR or (2) stabilisation or worsening of the viral load.Measure: Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5. Time: 5 days of treatment
Description: Duration of fever - duration of respiratory symptoms (cough, dyspnea) - duration of other COVID-19 related symptoms (digestive symptoms, ageusia, anosmia)Measure: Clinical evolution Time: up to 3 months
Description: Less or equal to 94% oxygen saturation - need to initiate oxygenotherapy - occurrence of respiratory distress - patient transfer in intensive care unit - need of mechanical ventilation - occurrence of non-respiratory organ failure - occurrence of septic shockMeasure: Proportion of patients progressing to a severe form Time: up to 3 months
Description: Date and cause of deathMeasure: Mortality Time: up to 1 and 3 months
Description: SARS-CoV-2 viral load by PCR on nasopharyngeal swab at day 10 (if positive at day 5) : rate of negativation and comparison of number of cycles with previous samplesMeasure: Evaluation of viral load drop Time: at day 10
Description: Frequence and causality of all-grade cardiac adverse events - frequence and causality of grade > 1 adverse events for other adverse events - frequence and causality of serious adverse events (CTCAE v5)Measure: Tolerance of study treatment Time: up to 3 months
Description: Collection of serum to realize serological testsMeasure: Evaluation of the seroconversion Time: at inclusion, day 10, day 30 and day 90 after treatment
Description: Phenotypic and functional study of NK lymphocytes at inclusion, Retrospective analysis on frozen cells.Measure: NK immunological study Time: at day 10 and day 30 after treatment
Description: Duration of hospitalisation (conventional, intensive care, reanimation)Measure: Hospitalisation duration Time: up to 3 months
Description: Patient follow-up during 3 months : hematological status and associated therapyMeasure: Impact of the study treatment on the treatment of the hematological disease Time: up to 3 months
Description: ECG (using connected machine to allow monitoring at home)Measure: Monitoring of the QT space Time: at inclusion, day 2, day 5, day 10
Description: Dosage of residual concentration of azithromycine and hydroxychloroquine.Measure: Dosage of residual concentration of azithromycine and hydroxychloroquine. Time: at day 5 and day 10
Description: Phenotypic and functional study of T lymphocytes at inclusion, Retrospective analysis on frozen cells.Measure: T immunological study Time: at day 10 and day 30 after treatment
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports